Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 17Terminated 6Active not recruiting 5Unknown 3Withdrawn 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Nivolumab 25pembrolizumab 20Ipilimumab 15toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Cyclophosphamide 6Blood Specimen Collection 6trametinib 5fludarabine 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5durvalumab 4binimetinib 4aldesleukin 4Interleukin-2 4Injections 4Carboplatin 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Paclitaxel 3Introns 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Melanoma × Introns × Clear all
NCT03435302 2018-02-19

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Peking University Cancer Hospital & Institute

Phase 3 Unknown
204 enrolled
Dermatologic

Melanoma

NCT01782508 2013-02-04

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
40 enrolled
Dermatologic

Melanoma

NCT00226408 2006-06-21

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Dermatologic Cooperative Oncology Group

Phase 3 Unknown
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡